Industry News

Medical Device Industry News

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

September 18th, 2026|Medical Device News Magazine|

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1. Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a